
    
      Subjects will be randomized to either Proellex dose, 25 mg or 50 mg, in a 1:1 ratio. Subjects
      will receive drug for a four (4) month cycle of therapy three (3) times, each treatment cycle
      being separated by an off-drug interval until menstruation occurs. During the treatment
      periods, all subjects will be assessed monthly. Subjects will undergo an additional follow-up
      for 3 months following their last treatment visit.
    
  